Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,1865,2-1,55
Msft2,10
Nokia4,30054,351-1,19
IBM-0,42
Mercedes-Benz Group AG68,1168,130,63
PFE1,40
01.02.2023 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 30.01.2023 23:20:00
Eisai (ESALF.PK, US Other OTC (Pink Sheets))
Závěr k 30.1.2023 Změna (%) Změna (USD) Objem obchodů (ks)
61,50 -3,20 -2,03 451
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 01.02.2023
Popis společnosti
Obecné informace
Název společnostiEisai Co., Ltd
Ticker4523
Kmenové akcie:Ordinary Shares
RIC4523.T
ISINJP3160400002
Poslední známé roční výsledky31.03.2021
Poslední známé čtvrtletní výsledky31.12.2021
Počet zaměstnanců k 31.03.2021 11 237
Akcie v oběhu k 31.12.2021 286 750 932
MěnaJPY
Kontaktní informace
UliceEisai Main Bldg., 4-6-10, Koishikawa
MěstoBUNKYO-KU
PSČ112-8088
ZeměJapan
Kontatní osobaShinichi Sagawa
Funkce kontaktní osobyDirector of Accounting in Main Finance & Accounting Unit
Telefon81 338 173 700
Fax81338113305
Kontatní telefon81 338 175 070

Business Summary: Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
Financial Summary: BRIEF: For the nine months ended 31 December 2021, Eisai Co., Ltd revenues increased 13% to Y565.33B. Net income increased 34% to Y60.36B. Revenues reflect Other Business segment increase of 23% to Y53.94B. Net income benefited from Pharmaceutical Business segment income increase of 48% to Y282.79B, Other Business segment income increase of 32% to Y49.97B, Japan segment income increase of 70% to Y119.61B.
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Process, Phys Dist & Log Consulting Services
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Process, Physical, Distribution and Logistics Consulting Services
SICPharmaceutical Preparations
SICManagement Consulting Services



  • Poslední aktualizace: 01.02.2023
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board of Directors, Independent DirectorYasuhiko Kato74
Chief Executive Officer, Representative Executive Officer, DirectorHaruo Naito73
Senior Managing Executive Officer, Chief Financial OfficerRyohei Yanagi59
Representative Executive Officer, Chief Operating OfficerYasushi Okada62
Executive Officer, Chief Compliance Officer, Chief Information Security OfficerMitsuaki Tanaka59
Senior Managing Executive Officer, General Counsel, President of SubsidiaryKenta Takahashi61
Managing Executive Officer, Chief Government Relations OfficerMasatomi Akana54
Managing Executive Officer, President of Neurology Business Group, Chairman of SubsidiaryIvan Cheung44
Managing Executive Officer, General Manager of SubsidiariesYanhui Feng49
Managing Executive Officer, Global Safety Officer, Chief Director of Global SafetyEdward Geary58